NEW YORK —
However, the 12-person panel declined to issue punitive damages, saying the company’s DePuy orthopedics unit, which made and marketed the all-metal device, did not act with fraud or malice. The implant, known as the Articular Surface Replacement, or ASR, was recalled in mid-2010.
In a statement, the company described the verdict as ‘‘mixed’’ and said that it planned to appeal the damage award. It disputed the finding by the jury that the ASR was defectively designed.
It was impossible to say what the verdict, which came in a Los Angeles state court, would mean for other ASR-related cases. A trial on a second lawsuit is scheduled to begin Monday in Chicago, with other cases expected to proceed later this year.
Some lawyers and industry analysts have estimated that the suits ultimately would cost Johnson & Johnson billions of dollars to resolve.
The ASR belonged to a class of once widely used hip replacements whose cup and ball components were both made of metal. It was first sold by DePuy in 2003 outside the United States for use in an alternative hip replacement procedure called resurfacing. Two years later, DePuy started selling another version of the ASR for use in the United States in standard hip replacements that used the same cup component as the resurfacing device.
However, the ASR’s design caused the cup and ball to strike against each other as a patient moved, resulting in the shedding of metallic debris. That debris inflamed and damaged tissue and bone, causing pain and, in some cases, permanent damages to patients.
Today, all-metal hips such as the ASR are rarely used by surgeons because most models suffered from similar problems. But data from orthopedic registries suggests that the ASR was far worse than many competing products.
An internal Johnson & Johnson document introduced at the Los Angeles trial estimated that close to 40 percent of patients who received an ASR will need to undergo a second operation within five years of the first to have the implant removed and replaced.
Traditional artificial hips, which are made of metal and plastic, are expected to last 15 years or more before needing to be replaced, and the normal replacement rate for early unexpected failures is about 5 percent after five years.
The lawsuit heard in Los Angeles was not originally scheduled to be the first over the ASR but it was moved up because the plaintiff, a former prison guard named Loren Kransky, was diagnosed with terminal cancer. Before the start of the Los Angeles trial, which began in late January, Kransky’s lawyers had not expected him to live through it.
Internal Johnson & Johnson documents that became public during the trial indicated that company executives were told by surgeons, who were also paid consultants to the device maker, that the design of the ASR was flawed.
In addition, some surgeons also urged the device maker to slow sales of the implant or stop them completely, records show.
In the case, evidence was also presented that showed that Johnson & Johnson considered redesigning the ASR to reduce its problems, but then abandoned the project because the implant’s sales did not justify the costs of the redesign. One of the DePuy executives involved in that decision was Andrew Ekdahl, who now heads Johnson & Johnson’s orthopedics division.
Johnson & Johnson executives such as Ekdahl have said throughout the ASR episode that they acted responsibly and moved to recall the device in 2010 when data from an orthopedic registry in Britain showed that its failure rate was higher than normal.
Before reaching its verdict Friday, the jury that heard Kransky’s case deliberated for more than five days.
In its decision, the panel ordered Johnson & Johnson to pay him some $338,000 to cover his medical expenses and $8 million to cover his pain and emotional suffering.